Jan 31, 2023 | Interviews
“Given the long-term success of Humira, which can cost patients up to $84,000 a year, initial uptake of the biosimilars may be limited, said Alex Brill, founder and CEO of economic policy consulting firm Matrix Global Advisors.”
Jan 26, 2023 | Analysis
MGA has released a new report today for the Coalition for Affordable Prescription Drugs (CAPD), “Patent Thickets and Lost Drug Savings.”
Aug 25, 2022 | Interviews
Alex Brill, a senior fellow at the American Enterprise Institute and CEO of Matrix Global Advisors, recently sat down with CAPD spokesperson Maura Keefe to discuss his latest report for CAPD.
Aug 16, 2022 | Press Releases
“The rebate rule came out of a concern about rising drug prices,” said Brill. “But it is a policy that is chock full of unintended consequences. If it were implemented, we’d have fewer discounts. That’s definitely not going to lower overall spending in the healthcare sector.”
Mar 21, 2022 | News
In his Forbes article, Ike Brannon discusses the blame game being played in Washington in regards to skyrocketing drug prices. MGA’s report “Understanding Drug Rebates and Their Role in Promoting Competition” was utilized by Brannon to bolster the argument that it is the drug companies who are responsible for drug pricing.